Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab

Ioannis Tomazos, J. Rafael Sierra, Karissa M. Johnston, Antoinette Cheung, Robert A. Brodsky, Ilene C. Weitz

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab'. Together they form a unique fingerprint.

Medicine & Life Sciences